ID: ALA2326072

Max Phase: Preclinical

Molecular Formula: C34H39NO2

Molecular Weight: 493.69

Molecule Type: Small molecule

Representations

Canonical SMILES:  C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCC#Cc4ccc(-n5cccc5)cc4)[C@H]3[C@@H]1CC[C@@H]2O

Standard InChI:  InChI=1S/C34H39NO2/c1-34-19-18-30-29-15-14-28(36)23-26(29)22-25(33(30)31(34)16-17-32(34)37)9-5-3-2-4-8-24-10-12-27(13-11-24)35-20-6-7-21-35/h6-7,10-15,20-21,23,25,30-33,36-37H,2-3,5,9,16-19,22H2,1H3/t25-,30-,31+,32+,33-,34+/m1/s1

Standard InChI Key:  XCPJWYKWACPRGL-GDOMDJCBSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 493.69

Molecular Weight (Monoisotopic): 493.2981

AlogP: 7.24

#Rotatable Bonds: 5

Polar Surface Area: 45.39

Molecular Species: NEUTRAL

HBA: 3

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 3

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 10.32

CX Basic pKa:

CX LogP: 8.38

CX LogD: 8.38

Aromatic Rings: 3

Heavy Atoms: 37

QED Weighted: 0.29

Np Likeness Score: 1.12

References

1. Jiang XR, Wang P, Smith CL, Zhu BT..  (2013)  Synthesis of novel estrogen receptor antagonists using metal-catalyzed coupling reactions and characterization of their biological activity.,  56  (7): [PMID:23448346] [10.1021/jm3013773]

Source

Source(1):

• Scientific Literature